Relevant bibliographies by topics / Surrogate endpoints / Books

Books on the topic 'Surrogate endpoints'

To see the other types of publications on this topic, follow the link: Surrogate endpoints.
Author: Grafiati
Published: 4 June 2021
Last updated: 8 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 20 books for your research on the topic 'Surrogate endpoints.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Burzykowski, Tomasz, Geert Molenberghs, and Marc Buyse, eds. The Evaluation of Surrogate Endpoints. New York, NY: Springer New York, 2005. http://dx.doi.org/10.1007/b138566.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Medicine), Roundtable for the Development of Drugs and Vaccines against AIDS (Institute of. Surrogate endpoints in evaluating the effectiveness of drugs against HIV infection and AIDS: September 11-12, 1989 : conference summary. Washington, D.C: National Academy Press, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Morganroth, Joel, and E. Neil Moore, eds. Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4613-1505-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Alonso, Ariel. Applied Surrogate Endpoint Evaluation Methods with SAS and R. Boca Raton : CRC Press, 2017.: Chapman and Hall/CRC, 2016. http://dx.doi.org/10.1201/9781315372662.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Institute of Medicine (U.S.). Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease, Institute of Medicine (U.S.). Board on Health Care Services, Institute of Medicine (U.S.). Board on Health Sciences Policy, Institute of Medicine (U.S.). Food and Nutrition Board, and National Academies Press (U.S.), eds. Perspectives on biomarker and surrogate endpoint evaluation: Discussion forum summary. Washington, D.C: National Academies Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Symposium on New Drugs and Devices (10th 1989 Philadelphia, Pa.). Use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia: Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31-November 1, 1989. Boston: Kluwer Academic Publishers, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kim, Sang-gyŏm. Saenghwahakchŏk pʻyojija mit taeri kyŏlgwa pyŏnsu ŭi PK/PD modelling chŏgyong e kwanhan yŏnʼgu =: The study for evaluation of PK/PD modeling using biomarker and surrogate endpoint. [Seoul]: Sikpʻum Ŭiyakpʻum Anjŏnchʻŏng, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

The Evaluation Of Surrogate Endpoints. Springer, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Molenberghs, Geert, Marc Buyse, and Tomasz Burzykowski. The Evaluation of Surrogate Endpoints. Springer, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wagner, J. A. Surrogate Endpoints in Medicine (Disease Markers). Ios Pr Inc, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
11

Downing, G. J. Biomarkers and Surrogate Endpoints: Clinical Research and Applications. Elsevier, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

Evaluation Of Biomarkers And Surrogate Endpoints In Chronic Disease. National Academies Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Washington, D.C.: National Academies Press, 2010. http://dx.doi.org/10.17226/12869.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

(Editor), Tomasz Burzykowski, Geert Molenberghs (Editor), and Marc Buyse (Editor), eds. The Evaluation of Surrogate Endpoints (Statistics for Biology and Health). Springer, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

Morganroth, J. Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia. Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Antiarrhythmic, Antiheart Failure and Hypolipidemic Agents (Developments in Cardiovascular Medicine). Springer, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
17

J, Downing Gregory, National Institutes of Health (U.S.), and United States. Food and Drug Administration., eds. Biomarkers and surrogate endpoints: Clinical research and applications : proceedings of the NIH-FDA conference held on 15-16 April 1999 in Bethesda, Maryland, USA. Amsterdam: Elsevier, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and ... & Devices, October 31 - November 1, 1989. Springer, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
19

Perspectives on Biomarker and Surrogate Endpoint Evaluation. Washington, D.C.: National Academies Press, 2011. http://dx.doi.org/10.17226/13038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Warwick, David. Prevention of thrombosis in orthopaedic surgery. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199550647.003.0006.

Full text
Abstract:
♦ The risk–benefit of thromboprophylaxis in orthopaedic surgery remains unclear♦ Some conditions, such as major trauma, carry a much higher risk than others, such as routine knee replacement♦ Some patients appear to be genetically more predisposed than others♦ In trials of efficacy of thromboembolism, the use of deep vein thrombosis as a surrogate endpoint for death from a pulmonary embolus may not be completely reliable♦ There is a variety of mechanical and chemical methods available, each of which has real and potential advantages as well as real and potential dangers♦ Even the length of time that a patient is at risk after major surgery is unclear♦ Clinicians should adhere to guidelines where possible.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Surrogate endpoints' for other source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography